MedTrace Logo

Endothelial Dysfunction After SCI

NCT07227727 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2025-11-14

No results posted yet for this study

Summary

This study plans to learn how endothelial cells, single cell lining of blood vessels may be dysfunctional after a spinal cord injury. Endothelial dysfunction will be measured by the capacity of blood vessels to vasodilate (increase in size) and alter blood flow is lower in adults with a spinal cord injury in comparison to adults without a spinal cord injury. The mechanisms which may alter this function may be critical in reducing the risk of heart attacks and strokes in people with spinal cord injuries.

Conditions

  • Spinal Cord Injuries
  • Endothelial Dysfunction

Interventions

PROCEDURE

Intra-arterial Infusion of Vasoactive Agents

A catheter is placed in the brachial artery of the non-dominant arm, and small doses of vasoactive drugs \[acetylcholine (Ach), isoproterenol (ISO), sodium nitroprusside (SNP)\] are infused. Forearm blood flow (FBF) is measured using venous occlusion plethysmography. The purpose of this procedure is to assess endothelium-dependent and independent vasodilation by stimulating different vascular pathways. The Ach infusion is to test muscarinic receptor, nitro oxide (NO) dependent, endothelium-dependent vasodilation. ISO infusion is to evaluate β-adrenergic, NO-dependent endothelium-dependent vasodilation. SNP infusion is to assess endothelium-independent vasodilation.

PROCEDURE

Intra-arterial Vitamin C Infusion

Vitamin C, a potent antioxidant, will be infused into the arm and forearm blood flow (FBF) will be re-evaluated to determine whether oxidative stress contributes to endothelial dysfunction.

PROCEDURE

Blood Sampling

Blood will be sampled from the antecubital vein (\~50 mL) for biomarker analysis. This is to assess circulating biochemical and molecular indicators of vascular health and inflammation including levels of endothelial cell derived microvesicles (EMVs)

Sponsors & Collaborators

  • University of Colorado, Boulder

    collaborator OTHER

  • Denver Health and Hospital Authority

    collaborator OTHER

  • Craig Hospital

    lead OTHER

Principal Investigators

  • Andrew Park, MD · Craig Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-07-31
Primary Completion
2027-07-30
Completion
2027-07-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07227727 on ClinicalTrials.gov